Project Grant R01HL171715
Award Date
7/15/24
Completion Date
5/31/29
Dollars Obligated
$583K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
This Project Grant award of $198,720.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research led by Dr. Anthony Sochet at The Johns Hopkins University to investigate the impact of invasive mechanical ventilation on functional fibrinolysis and thromboinflammation, and to develop an enhanced risk prediction model for hospital-acquired venous thromboembolism in critically ill children. The research aims to inform the design of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $180,199 to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The objective is to identify myeloid-derived suppressor cells (MDSC) as contributors to the immune response in children with viral lower respiratory tract infections (LRTI) and to investigate the PD-1 pathway as a potential therapeutic...
This Project Grant award of $726,408 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to define the role of endothelial TFEB in mitigating cardiovascular toxicity induced by cancer therapies. The award recipient, the University of Cincinnati, will leverage its expertise in endothelial cell biology and transgenic mouse models to explore how modulating the TFEB pathway can protect against...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $234,000.00 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to conduct secondary analysis of noninvasive imaging biomarkers for early prediction of single ventricle heart disease (SVD) failure. The project aims to noninvasively quantify systemic and pulmonary vascular compliance through...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,999,247 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Childrens Hospital Medical Center in Cincinnati, OH. The grant, entitled "Allogeneic Virus-Specific T-Cell Therapy After Hematopoietic Stem Cell Transplant: Determinants of Treatment Success and Failure", aims to improve understanding of the mechanisms underlying success and failure of virus-specific T-cell (VST) therapy in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,588 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant supports the career development of Dr. Son Duong, a clinician-scientist specializing in pediatric cardiology and advanced cardiovascular imaging, into an independent investigator. The primary objectives are to: 1) Develop and validate a prediction tool for right ventricular volumes...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,398,734 to the University of California, Merced to conduct research on understanding the role of the blood vascular system and endothelial cells in early thymus regeneration after cytotoxic treatments. The project aims to utilize novel intravital imaging techniques to directly analyze the live thymus and characterize the impact...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...
This federal Project Grant award of $680,583 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Mayo Clinic supports research focused on discovering genetic modifiers and therapies for anthracycline-induced cardiotoxicity. The key objectives are to: Confirm FABP7 and GPNMB as therapeutic target genes for anthracycline-induced cardiotoxicity, and explore the role of cardiac aging using the killifish model. Test the hypothesis that epicardial...